In the Claims:

Please amend Claims 1, 2 and 13, cancel claims 15-17 and add new claims 26-37 as follows:

1. (Amended) A therapeutic composition having a high yield of fibrinogen and being effective on contact with thrombin at a site of treatment in a patient as a tissue adhesive, hemostat or sealant, said composition comprising non-autologous, non-single donor mammalian fibrinogen from a sample of non-human, mammalian blood plasma with polyethylene glycol such that at least about 90% of the fibrinogen present in said sample is recovered, wherein said fibrinogen [that] is capable of polymerizing when provided in solution at said site at a concentration of about 10 mg/ml thereof or less, to a fibrin network having therapeutically effective strength, and further comprising a sufficient amount of one or more physiologically-compatible solutes such that said composition, if formulated as a lyophilized material, can be reconstituted therefrom at room temperature in sterile water for injection in about 30 minutes or less, at about 25 mg/ml of said fibrinogen, said fibrinogen being made present at said site of treatment at a concentration of about 10 mg/ml or less.

2. (Amended) A therapeutic composition having a high yield of fibrinogen and being effective on contact with thrombin at a site of treatment in a patient as a tissue adhesive, hemostat or sealant, said composition comprising non-autologous, non-single donor mammalian fibrinogen from a sample of non-human, mammalian blood plasma with polyethylene glycol such that at least about 90% of the fibrinogen present in said sample is recovered, wherein said fibrinogen [that] is capable of polymerizing when provided in solution at said site at a concentration of about 30 mg/ml thereof or less, to a fibrin network having therapeutically effective strength, wherein said composition contains less than about 30% (w/w), based on total protein mass present therein, of proteins other than fibrinogen, and further comprises a sufficient amount of one or more low molecular weight physiologically-compatible solutes such that said composition, if formulated as a lyophilized

material, can be reconstituted therefrom at room temperature in sterile water for injection in about 30 minutes or less, at about 25 mg/ml of said fibrinogen, said fibrinogen being made present at said site of treatment at a concentration of about 30 mg/ml or less.

13. (Amended) A reactive therapeutic composition having a high yield of fibrinogen and being effective on contact at a site of treatment in a patient as a tissue adhesive, hemostat or sealant, said composition comprising, per milliliter thereof, between about 0.05 and about 500 NIH units of thrombin and also, per milliliter, between about 5 and about 30 mg of fibrinogen from a sample of non-human, mammalian blood plasma with polyethylene glycol such that at least about 90% of the fibrinogen present in said sample is recovered, said fibrinogen being capable of being polymerized to a fibrin network having therapeutically effective strength, when present at said site at [said] a concentration of about 30 mg/ml or less.

Cancel Claim 15.

Cancel Claim 16.

Cancel Claim 17.

--26. (New) A therapeutic composition of Claim 2 produced according to a method comprising three or more steps including at least the steps of:

(A) precipitating fibrinogen from a sample of mammalian blood sample with polyethylene glycol 1000;

(B) resuspending said fibrinogen in solution; and

(C) reprecipitating said fibrinogen with gylcine; wherein precipitation of said fibrinogen with polyethylene glycol is performed only once.--

--27. (New) A method for inducing tissue adhesion, sealing of tissue, or hemostatis in a mammalian patient at a site of treatment therein comprising contacting said site with a therapeutically effective amount of a therapeutic composition according to Claim 2.--

--28. (New) A method according to Claim 27 further comprising contacting said site or said composition with an amount of thrombin effective to convert fibrinogen of said composition to a fibrin network having therapeutically effective strength.--

--29. (New) A method according to Claim 28 wherein the amount of thrombin utilized therein is from about 0.1 NIH unit up to about 1000 NIH units thereof per milliliter of fibrinogen-containing therapeutic composition utilized therein.--

--30. (New) A method according to Claim 29 wherein said amount of thrombin is from about 1.0 NIH unit up to about 300 NIH units thereof.--

--31. (New) A method according to Claim 28 wherein said thrombin and said fibrinogen-containing therapeutic composition are applied separately to said site of treatment.--

--32. (New) A method according to Claim 28 wherein said thrombin and said fibrinogen-containing therapeutic composition are applied concurrently to said site of treatment.--

--33. (New) A method according to Claim 28 wherein said thrombin and said fibrinogen-containing therapeutic composition are first combined and then applied to said site of treatment.--

--34. (New) A method according to Claim 27 wherein said fibrinogen-containing therapeutic composition that contacts said site of treatment is in the form of a dry lyophilized powder.--

--35. (New) A therapeutic composition according to Claim 1 prepared as a lyophilized material.--

--36. (New) A therapeutic composition having a high yield of fibrinogen and being effective on contact with thrombin at a site of treatment in a patient as a tissue adhesive, hemostat or sealant, said composition comprising non-autologous, non-single donor mammalian fibrinogen that is capable of polymerizing when provided in solution at said site at a concentration of about 10 mg/ml thereof or less, to a fibrin network having therapeutically effective strength, and further comprising a sufficient amount of one or more physiologically-compatible solutes such that said composition, if formulated as a lyophilized material, can be reconstituted therefrom at room temperature in sterile water for injection in about 30 minutes or less, at about 25 mg/ml of said fibrinogen; wherein said therapeutic composition is prepared by the following steps: (A) precipitating said fibrinogen from a sample of non-human mammalian blood plasma with polyethylene glycol 1000; (B) resuspending said fibrinogen in solution; and (C) reprecipitating said fibrinogen with glycine, wherein reprecipitation of said fibrinogen with polyethylene glycol is performed only once and at least about 90% of the fibrinogen present in said sample is recovered, said fibrinogen being made present at said site of treatment at a concentration of about 10 mg/ml or less.--

--37. (New) A therapeutic composition having a high yield of fibrinogen and being effective on contact with thrombin at a site of treatment in a patient as a tissue adhesive, hemostat or sealant, said composition comprising non-autologous, non-single donor mammalian fibrinogen that is capable of polymerizing when provided in solution at said site at a concentration of about 30 mg/ml thereof or less, to a fibrin network having

therapeutically effective strength, wherein said composition contains less than about 30% (w/w), based on total protein mass present therein, of proteins other than fibrinogen, and further comprises a sufficient amount of one or more low molecular weight physiologically compatible solutes such that said composition, if formulated as a lyophilized material, can be reconstituted therefrom at room temperature in sterile water for injection in about 30 minutes or less, at about 25 mg/ml of said fibrinogen; wherein said therapeutic composition is prepared by the following steps: (A) precipitating said fibrinogen from a sample of non-human mammalian blood plasma with polyethylene glycol 1000; (B) resuspending said fibrinogen in solution; and (C) reprecipitating said fibrinogen with glycine, wherein reprecipitation of said fibrinogen with polyethylene glycol is performed only once and at least about 90% of the fibrinogen present in said sample is recovered, said fibrinogen being made present at said site of treatment at a concentration of about 30 mg/ml or less.--

3 CONCLUD.

**Remarks**

Claims 1-25 are pending in this continuation application. Of those claims, Applicants herein cancel Claims 15-17 and amend Claims 1, 2 and 13. Applicants also add new Claims 26-34 which correspond, in part, to Claims 40-48, withdrawn as a result of a restriction requirement in now abandoned parent application Serial No. 08/805,703. Applicants also add Claims 35-37 which correspond, in part, to Claims 49-51 of said parent application. Accordingly, Claims 1-14 and 18-37 are presently pending in the subject application.

All pending claims are believed to be sufficiently related to warrant their consideration in a single application. It is therefore respectfully submitted that the present claims and remarks place the subject application in condition for allowance.

Specifically, independent Claims 1, 2, 13, 36 and 37 specify a therapeutic composition "having a high yield of fibrinogen." Claims 1, 2 and 13 have also been